P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate

Toxicology and Applied Pharmacology

Volumn 306, Issue , 2016, Pages 27-35

  Jia, Yongming ^a   Liu, Zhihao ^a   Wang, Changyuan ^a   Meng, Qiang ^a   Huo, Xiaokui ^a   Liu, Qi ^a   Sun, Huijun ^a   Sun, Pengyuan ^a   Yang, Xiaobo ^a   Ma, Xiaodong ^a   Liu, Kexin ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Drug drug interaction; Methotrexate; Resveratrol; Transporter

Indexed keywords

METHOTREXATE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; RESVERATROL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; ORGANIC ANION TRANSPORTER; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APPARENT PERMEABILITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY ASSAY; DRUG ABSORPTION; DRUG EFFECT; DRUG HALF LIFE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; INTESTINE INJURY; MALE; MAXIMUM PLASMA CONCENTRATION; NEPHROTOXICITY; NONHUMAN; PHARMACOKINETIC PARAMETERS; RAT; RENAL CLEARANCE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION; ANIMAL; CELL SURVIVAL; DRUG EFFECTS; DRUG INTERACTION; HEK293 CELL LINE; INTESTINE; KIDNEY; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; CELL SURVIVAL; DRUG INTERACTIONS; HEK293 CELLS; HUMANS; INTESTINAL ABSORPTION; INTESTINES; KIDNEY; MALE; METHOTREXATE; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; P-GLYCOPROTEIN; RATS, WISTAR; RENAL ELIMINATION; STILBENES;

EID: 84977080616     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2016.06.030     Document Type: Article

References (32)

1. Chioukh, R., Noel-Hudson, M.S., Ribes, S., Fournier, N., Becquemont, L., Verstuyft, C., Proton pump inhibitors inhibit methotrexate transport by renal basolateral organic anion transporter hOAT3. Drug Metab. Dispos. 42 (2014), 2041–2048.
2. Choi, C.H., ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int., 5, 2005, 30.
3. Choi, J.S., Choi, B.C., Kang, K.W., Effect of resveratrol on the pharmacokinetics of oral and intravenous nicardipine in rats: possible role of P-glycoprotein inhibition by resveratrol. Pharmazie 64 (2009), 49–52.
4. Colom, H., Alfaras, I., Maijo, M., Juan, M.E., Planas, J.M., Population pharmacokinetic modeling of trans-resveratrol and its glucuronide and sulfate conjugates after oral and intravenous administration in rats. Pharm. Res. 28 (2011), 1606–1621.
5. Dubey, R.K., Jackson, E.K., Gillespie, D.G., Zacharia, L.C., Imthurn, B., Rosselli, M., Resveratrol, a red wine constituent, blocks the antimitogenic effects of estradiol on human female coronary artery smooth muscle cells. J. Clin. Endocrinol. Metab. 95 (2010), E9–17.
6. Emami Riedmaier, A., Nies, A.T., Schaeffeler, E., Schwab, M., Organic anion transporters and their implications in pharmacotherapy. Pharmacol. Rev. 64 (2012), 421–449.
7. Endres, C.J., Hsiao, P., Chung, F.S., Unadkat, J.D., The role of transporters in drug interactions. Eur. J. Pharm. Sci. 27 (2006), 501–517.
8. Fukuhara, K., Ikawa, K., Morikawa, N., Kumagai, K., Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data. J. Clin. Pharm. Ther. 33 (2008), 677–684.
9. Gupta, S.C., Kannappan, R., Reuter, S., Kim, J.H., Aggarwal, B.B., Chemosensitization of tumors by resveratrol. Ann. N. Y. Acad. Sci. 1215 (2011), 150–160.
10. Hagos, Y., Wolff, N.A., Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity. Toxins (Basel) 2 (2010), 2055–2082.
11. Hess, J.A., Khasawneh, M.K., Cancer metabolism and oxidative stress: insights into carcinogenesis and chemotherapy via the non-dihydrofolate reductase effects of methotrexate. BBA Clin. 3 (2015), 152–161.
12. Huo, X., Liu, Q., Wang, C., Meng, Q., Sun, H., Peng, J., Ma, X., Liu, K., Enhancement effect of P-gp inhibitors on the intestinal absorption and antiproliferative activity of bestatin. Eur. J. Pharm. Sci. 50 (2013), 420–428.
13. Jia, Y., Liu, Z., Huo, X., Wang, C., Meng, Q., Liu, Q., Sun, H., Sun, P., Yang, X., Shu, X., Liu, K., Enhancement effect of resveratrol on the intestinal absorption of bestatin by regulating PEPT1, MDR1 and MRP2 in vivo and in vitro. Int. J. Pharm. 495 (2015), 588–598.
14. Kato, S., Ito, K., Kato, Y., Wakayama, T., Kubo, Y., Iseki, S., Tsuji, A., Involvement of multidrug resistance-associated protein 1 in intestinal toxicity of methotrexate. Pharm. Res. 26 (2009), 1467–1476.
15. Kong, L.L., Zhuang, X.M., Yang, H.Y., Yuan, M., Xu, L., Li, H., Inhibition of P-glycoprotein Gene expression and function enhances triptolide-induced hepatotoxicity in mice. Sci. Rep., 5, 2015, 11747.
16. Krause, A.S., Weihrauch, M.R., Bode, U., Fleischhack, G., Elter, T., Heuer, T., Engert, A., Diehl, V., Josting, A., Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy. Leuk. Lymphoma 43 (2002), 2139–2143.
17. Lau, Y.Y., Huang, Y., Frassetto, L., Benet, L.Z., Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin. Pharmacol. Ther. 81 (2007), 194–204.
18. Liu, Z., Liu, K., Application of model-based approaches to evaluate hepatic transporter-mediated drug clearance: in vitro, in vivo, and in vitro-in vivo extrapolation. Curr. Drug Metab. 17 (2016), 456–468.
19. Liu, Q., Wang, C., Meng, Q., Huo, X., Sun, H., Peng, J., Ma, X., Sun, P., Liu, K., MDR1 and OAT1/OAT3 mediate the drug-drug interaction between puerarin and methotrexate. Pharm. Res. 31 (2014), 1120–1132.
20. Maeda, A., Tsuruoka, S., Kanai, Y., Endou, H., Saito, K., Miyamoto, E., Fujimura, A., Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporter 3-transfected cells. Eur. J. Pharmacol. 596 (2008), 166–172.
21. Morrissey, K.M., Stocker, S.L., Wittwer, M.B., Xu, L., Giacomini, K.M., Renal transporters in drug development. Annu. Rev. Pharmacol. Toxicol. 53 (2013), 503–529.
22. Rossi, D., Guerrini, A., Bruni, R., Brognara, E., Borgatti, M., Gambari, R., Maietti, S., Sacchetti, G., trans-Resveratrol in nutraceuticals: issues in retail quality and effectiveness. Molecules 17 (2012), 12393–12405.
23. Shitara, Y., Sato, H., Sugiyama, Y., Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol. 45 (2005), 689–723.
24. Vlaming, M.L., Pala, Z., van Esch, A., Wagenaar, E., van Tellingen, O., de Waart, D.R., Oude Elferink, R.P., van de Wetering, K., Schinkel, A.H., Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. Clin. Cancer Res. 14 (2008), 8152–8160.
25. Volk, E.L., Rohde, K., Rhee, M., McGuire, J.J., Doyle, L.A., Ross, D.D., Schneider, E., Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res. 60 (2000), 3514–3521.
26. Wang, C., Wang, C., Liu, Q., Meng, Q., Cang, J., Sun, H., Peng, J., Ma, X., Huo, X., Liu, K., Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab. Dispos. 42 (2014), 996–1007.
27. Wang, L., Wang, C., Jia, Y., Liu, Z., Shu, X., Liu, K., Resveratrol increases anti-proliferative activity of Bestatin through downregulating P-glycoprotein expression via inhibiting PI3K/Akt/mTOR pathway in K562/ADR cells. J. Cell. Biochem. 117 (2016), 1233–1239.
28. Yulug, E., Turedi, S., Alver, A., Turedi, S., Kahraman, C., Effects of resveratrol on methotrexate-induced intestinal injury. Bratisl. Lek. Listy 116 (2015), 676–680.
29. Zamek-Gliszczynski, M.J., Chu, X., Polli, J.W., Paine, M.F., Galetin, A., Understanding the transport properties of metabolites: case studies and considerations for drug development. Drug Metab. Dispos. 42 (2014), 650–664.
30. Zhang, L., Zhang, Y.D., Zhao, P., Huang, S.M., Predicting drug-drug interactions: an FDA perspective. AAPS J. 11 (2009), 300–306.
31. Zhang, J., Wang, C., Liu, Q., Meng, Q., Cang, J., Sun, H., Gao, Y., Kaku, T., Liu, K., Pharmacokinetic interaction between JBP485 and cephalexin in rats. Drug Metab. Dispos. 38 (2010), 930–938.
32. Zhu, Y., Meng, Q., Wang, C., Liu, Q., Huo, X., Zhang, A., Sun, P., Sun, H., Li, H., Liu, K., Methotrexate-bestatin interaction: involvement of P-glycoprotein and organic anion transporters in rats. Int. J. Pharm. 465 (2014), 368–377.